CTMC - a joint venture between Resilience + MD Anderson Cancer Center

CTMC, a joint venture between Resilience and MD Anderson Cancer Center, is dedicated to accelerating the development and manufacturing of innovative cell therapies to cure cancer. Established in 2022, CTMC aims to leverage the expertise of Resilience as a leading complex biologics manufacturing technology organization and the renowned MD Anderson Cancer Center to drive innovation from academia and biotech and expedite the impact of Cell Therapy for cancer patients.

With a focus on the Biopharma and Biotechnology industries, CTMC is headquartered in the United States. As of now, there is no publicly disclosed information regarding the last investment or the investors involved in CTMC.